Phase 2 Trial of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination
with standard of care docetaxel in patients with metastatic castration resistant prostate
cancer. Docetaxel is a taxane chemotherapy which has been shown to prolong survival in men
with castration resistant prostate cancer. Cirmtuzumab is a monoclonal antibody that targets
the receptor called ROR1 of the non-canonical Wnt pathway and is suspected to contribute to
prostate cancer growth and progression.